期刊
CURRENT RHEUMATOLOGY REPORTS
卷 21, 期 7, 页码 -出版社
SPRINGER
DOI: 10.1007/s11926-019-0835-8
关键词
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; Remission induction; remission maintenance; Cyclophosphamide; Rituximab; Mycophenolate mofetil; Plasma exchange
类别
Purpose of ReviewThe long-term survival of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has improved dramatically as a direct result of evolving therapy. This review summarizes evidence-based treatment strategies with currently approved immunosuppressive medications to serve as a guide for practitioners in the management of patients with AAV.Recent FindingsTargeted therapy aimed at minimizing treatment-related adverse effects while optimizing effectiveness is a propagated approach. Such tailored therapy considers disease severity and is especially warranted in those at high risk for relapsing vasculitis.SummaryAs treatment options for AAV become available, the need to tailor therapy has become increasingly relevant to optimize patient outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据